产品目录
| 编号 | 化学名称 | Cas号 | 纯度 | 化学结构 |
|---|---|---|---|---|
| 615201 | CLEFMA | 1246964-32-8 | 98% Min. |  |
| CLEFMA has anti-proliferative activity in H441 cells. CLEFMA may induce autophagic ce | ||||
| 2062004 | [(1R,2S)-2-(3-fluorophenyl)-2-(hydroxymethyl)cyclopropyl]-methyl acetate | 1369768-29-5 | ≧95.0% | -2-(3-fluorophenyl)-2-(hydroxymethyl)cyclopropyl)methyl_acetate_1369768-29-5.gif) |
| 262324 | 2-(3-Fluoro-4-isopropoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane | 1350426-06-0 | 98% Min. | -4,4,5,5-tetramethyl-1,3,2-dioxaborolane_1350426-06-0.png) |
| 20732 | Lanraplenib | 1800046-95-0 | 98% |  |
| GS-9876（lanraplenib）是一种高度选择性的口服SYK抑制剂，主要用于狼 | ||||
| 52004 | Belnacasan | 273404-37-8 | 98% | _273404-37-8.png) |
| Belnacasan (VX-765) 是 VRT-043198 的口服生物活性前药，VRT-043198 是有效 | ||||
| 2071401 | Pimodivir ( VX-787 ) | 1629869-44-8 | 98% Min. |  |
| Pimodivir (VX-787) 是一种可口服的甲型流感病毒聚合酶抑制剂，通过 | ||||
| 2073107 | Trilaciclib hydrochloride (G1T28 hydrochloride) | 1977495-97-8 | 98% Min. |  |
| Trilaciclib是一种小分子竞争性细胞周期蛋白依赖性激酶4和6（CDK4 / | ||||
| 2073108 | PF-06802861 ( ARRY 371797 ; ARRY-797 ) | 1034189-82-6 | ≧98.0% | _1034189-82-6.png) |
| ARRY 797（也称为ARRY 371797或PF 06802861）是一种具有口服活性，选择性 | ||||
| 208191 | OATD-01 (GLPG-4716) | 2088453-21-6 | ≧98.0% |  |
| OATD-01 (GLPG-4716)是一种有效的酸性哺乳动物几丁质酶（AMCase）和壳 | ||||
| 2091501 | AB-680 | 2105904-82-1 | 98% Min. |  |
| AB-680一种是高效、可逆和选择性CD73抑制剂。AB-680是第一个临床使 | ||||
| 2091502 | 5-(chloromethyl)-1-propyl-1H-imidazole hydrochloride | 497223-15-1 | ≧95.0% | -1-propyl-1H-imidazole_hydrochloride_497223-15-1.png) |
| 5-(chloromethyl)-1-propyl-1H-imidazole hydrochloride 是合成 Cenicriviroc ( TAK-652 | ||||
| 20103001 | ASN007 | 2055597-12-9 | ≧98.0% |  |
| ASN007 , a novel oral ERK inhibitor , has shown anti-tumor activity in both solid tum | ||||